SGMO: Sangamo Therapeutics PEG Multiple

Brandmark of sangamo.com (SGMO)

Geopolitical tensions are hindering global DNA therapy trials, triggering volatility. The P/E ratio and EPS growth on the GURU.Markets chart confirm this, where the value 0.00 represents the current metric. Air delivery of biomaterials and robotic zinc finger design, which automates sample screening to accelerate commercialization for Sangamo Therapeutics (SGMO), are restoring stability.

SGMO Sangamo Therapeutics: Price/Earnings to Growth Ratio in the range 07/04/2022 - 05/09/2026

Sangamo Therapeutics (SGMO) - metric breakdowns and financial figures

- market value and analyst target forecast:
General company analysis:Sangamo, SGMO
Finished products of Sangamo BioSciences

Investment risks in Sangamo Therapeutics (SGMO) require an analysis of profit dynamics relative to market value, where values below one signal that the asset is undervalued. By examining the weighted PEG ratio, an investor can assess how the company's capitalization aligns with the scaling rates of its unique zinc finger platform for precision DNA editing, distinguishing a potential "moonshot" from a fundamental crisis.

Competing companies

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Corp)|PEG Multiple TSHA|PEG Multiple uniqure.com (QURE)|Price/Earnings to Growth Ratio MeiraGTx PLC MGTX|Growth-Adjusted Payback Ratio RGNX|solidbio.com - PEG Multiple|OCGN (Ocugen Pharma) - Growth-Adjusted P/E Ratio|PACB: PEG Multiple|Benitec Biopharma (BNTC) - PEG Multiple|DSGN (Design Therapeutics Inc) - PEG Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Growth-Adjusted Market Cap to Net Income|FDMT - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio LXEO (Lexeo)|Price/Earnings to Growth Ratio korrobio.com KRRO|Growth-Adjusted Market Cap to Net Income Editas Medicine, Inc. (EDIT)|SLN - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income ProQR PRQR|CDXS: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income